Skip to main content
Top

25-10-2024 | Chronic Kidney Disease | Review

Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?

Authors: Mehmet Kanbay, Sidar Copur, Zeynep Y. Yilmaz, Francesca Mallamaci, Carmine Zoccali

Published in: Journal of Nephrology

Login to get access

Abstract

Anemia of chronic kidney disease is a multifactorial condition secondary to various etiologies, including nutritional deficiencies, chronic inflammation, erythropoietin deficiency or resistance, bone marrow suppression, iron deficiency and adverse drug effects. The major therapeutic intervention for anemia among chronic kidney disease patients is erythropoiesis-stimulating agents. However, a limitation of erythropoiesis-stimulating agents is the risk for thromboembolic events, hypertension, seizures, solid organ malignancies and hyporesponsiveness. A novel interleukin-6 monoclonal antibody, ziltivekimab, has been evaluated for managing anemia in chronic kidney disease patients in pilot clinical trials with promising outcomes, including an improvement in hemoglobin levels and reduction of inflammatory parameters. These trials have shown that ziltivekimab does not increase the risk for cytopenia or infectious complications as has been described for other interleukin-6-targeting monoclonal antibodies, like tocilizumab. Furthermore, potentially beneficial effects on serum lipid profile have been reported, leading to the hypothesis of a favorable impact of the drug on atherosclerotic complications. In addition, ziltivekimab has shown efficacy in improving anemia parameters, including hemoglobin levels and iron studies. Ziltivekimab deserves full scale clinical development, and to this aim, large-scale clinical trials are under way.

Graphical abstract

Literature
1.
go back to reference Kovesdy CP, Davis JR, Duling I, Little DJ (2023) Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999–2018 national health and nutrition examination survey. Clin Kidney J 16:303–311PubMedCrossRef Kovesdy CP, Davis JR, Duling I, Little DJ (2023) Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999–2018 national health and nutrition examination survey. Clin Kidney J 16:303–311PubMedCrossRef
2.
go back to reference Bishaw F, Belay Woldemariam M, Mekonen G, Birhanu B, Abebe A (2023) Prevalence of anemia and its predictors among patients with chronic kidney disease admitted to a teaching hospital in Ethiopia: a hospital-based cross-sectional study. Med (Baltim) 102:e31797CrossRef Bishaw F, Belay Woldemariam M, Mekonen G, Birhanu B, Abebe A (2023) Prevalence of anemia and its predictors among patients with chronic kidney disease admitted to a teaching hospital in Ethiopia: a hospital-based cross-sectional study. Med (Baltim) 102:e31797CrossRef
4.
go back to reference Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A (2010) Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif 29:1–12PubMedCrossRef Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A (2010) Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif 29:1–12PubMedCrossRef
5.
go back to reference Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, Tangri N, Waikar SS, Więcek A, Cheung M, Jadoul M, Winkelmayer WC, Wheeler DC (2023) Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 104:655–680PubMedCrossRef Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, Tangri N, Waikar SS, Więcek A, Cheung M, Jadoul M, Winkelmayer WC, Wheeler DC (2023) Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 104:655–680PubMedCrossRef
6.
go back to reference Santos EJF, Dias RSC, Lima JFB, Salgado Filho N, Miranda Dos Santos A (2020) Erythropoietin resistance in patients with chronic kidney disease: current perspectives. Int J Nephrol Renovasc Dis 13:231–237PubMedPubMedCentralCrossRef Santos EJF, Dias RSC, Lima JFB, Salgado Filho N, Miranda Dos Santos A (2020) Erythropoietin resistance in patients with chronic kidney disease: current perspectives. Int J Nephrol Renovasc Dis 13:231–237PubMedPubMedCentralCrossRef
7.
go back to reference Schoener B, Borger J (2024) Erythropoietin stimulating agents. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024. StatPearls Publishing LLC, St Petersburg Schoener B, Borger J (2024) Erythropoietin stimulating agents. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024. StatPearls Publishing LLC, St Petersburg
8.
go back to reference Xu B, Liu S, Li Y, Zhao L, Song X, Chen T (2021) Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia. Clin Kidney J 14:2444–2445PubMedPubMedCentralCrossRef Xu B, Liu S, Li Y, Zhao L, Song X, Chen T (2021) Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia. Clin Kidney J 14:2444–2445PubMedPubMedCentralCrossRef
9.
go back to reference Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, Mariat C (2021) Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl 36:1616–1628CrossRef Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, Mariat C (2021) Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl 36:1616–1628CrossRef
10.
go back to reference Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M (2011) Renal anemia of inflammation: the name is self-explanatory. Blood Purif 32:220–225PubMedCrossRef Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M (2011) Renal anemia of inflammation: the name is self-explanatory. Blood Purif 32:220–225PubMedCrossRef
11.
go back to reference Solak Y, Cetiner M, Siriopol D, Tarim K, Afsar B, Covic A, Kanbay M (2016) Novel masters of erythropoiesis: hypoxia inducible factors and recent advances in anemia of renal disease. Blood Purif 42:160–167PubMedCrossRef Solak Y, Cetiner M, Siriopol D, Tarim K, Afsar B, Covic A, Kanbay M (2016) Novel masters of erythropoiesis: hypoxia inducible factors and recent advances in anemia of renal disease. Blood Purif 42:160–167PubMedCrossRef
12.
go back to reference Zoccali C, Mallamaci F (2023) Innate immunity system in patients with cardiovascular and kidney disease. Circ Res 132:915–932PubMedCrossRef Zoccali C, Mallamaci F (2023) Innate immunity system in patients with cardiovascular and kidney disease. Circ Res 132:915–932PubMedCrossRef
13.
go back to reference Ortiz A (2022) RICORS2040: the need for collaborative research in chronic kidney disease. Clin Kidney J 15:372–387PubMedCrossRef Ortiz A (2022) RICORS2040: the need for collaborative research in chronic kidney disease. Clin Kidney J 15:372–387PubMedCrossRef
14.
go back to reference Ortiz A, Wanner C, Gansevoort R (2023) Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the council of the European renal association. Clin Kidney J 16:403–407PubMedCrossRef Ortiz A, Wanner C, Gansevoort R (2023) Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the council of the European renal association. Clin Kidney J 16:403–407PubMedCrossRef
15.
go back to reference ERA-EDTA Council, ERACODA Working Group (2021) Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transpl 36:87–94CrossRef ERA-EDTA Council, ERACODA Working Group (2021) Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transpl 36:87–94CrossRef
16.
go back to reference Kanbay M, Demiray A, Afsar B, Covic A, Tapoi L, Ureche C, Ortiz A (2021) Role of klotho in the development of essential hypertension. Hypertension 77:740–750PubMedCrossRef Kanbay M, Demiray A, Afsar B, Covic A, Tapoi L, Ureche C, Ortiz A (2021) Role of klotho in the development of essential hypertension. Hypertension 77:740–750PubMedCrossRef
17.
go back to reference Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G (2017) The systemic nature of CKD. Nat Rev Nephrol 13:344–358PubMedCrossRef Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G (2017) The systemic nature of CKD. Nat Rev Nephrol 13:344–358PubMedCrossRef
18.
go back to reference Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P, Pannu N, Himmelfarb J, Hemmelgarn BR (2018) Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open 1:e184852PubMedPubMedCentralCrossRef Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P, Pannu N, Himmelfarb J, Hemmelgarn BR (2018) Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open 1:e184852PubMedPubMedCentralCrossRef
19.
go back to reference Wyld MLR, Morton RL, Clayton P, Wong MG, Jardine M, Polkinghorne K, Chadban S (2019) The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Qual Life Res 28:2081–2090PubMedCrossRef Wyld MLR, Morton RL, Clayton P, Wong MG, Jardine M, Polkinghorne K, Chadban S (2019) The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Qual Life Res 28:2081–2090PubMedCrossRef
20.
go back to reference McElvaney OJ, Curley GF, Rose-John S, McElvaney NG (2021) Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med 9:643–654PubMedPubMedCentralCrossRef McElvaney OJ, Curley GF, Rose-John S, McElvaney NG (2021) Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med 9:643–654PubMedPubMedCentralCrossRef
21.
go back to reference Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16:335–345PubMedPubMedCentralCrossRef Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16:335–345PubMedPubMedCentralCrossRef
22.
go back to reference Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, Zhang X, Peng A, Najjar R, Williamson S, Myers C, Sethi S, Lim K, Choi J, Gillespie M, Tang J, Jordan SC (2022) Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transpl 22:1133–1144CrossRef Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, Zhang X, Peng A, Najjar R, Williamson S, Myers C, Sethi S, Lim K, Choi J, Gillespie M, Tang J, Jordan SC (2022) Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transpl 22:1133–1144CrossRef
23.
go back to reference Nickerson PW, Böhmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A (2022) Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design. Trials 23:1042PubMedPubMedCentralCrossRef Nickerson PW, Böhmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A (2022) Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design. Trials 23:1042PubMedPubMedCentralCrossRef
24.
go back to reference Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH (2021) Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind placebo controlled trial. J Am Soc Nephrol 32:211–222PubMedCrossRef Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH (2021) Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind placebo controlled trial. J Am Soc Nephrol 32:211–222PubMedCrossRef
25.
go back to reference Nowak KL, Kakkar R, Devalaraja M, Lo L, Park W, Gobburu J, Kling D, Davidson M, Chonchol M (2021) A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD. Kidney 360 2:224–235PubMedCrossRef Nowak KL, Kakkar R, Devalaraja M, Lo L, Park W, Gobburu J, Kling D, Davidson M, Chonchol M (2021) A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD. Kidney 360 2:224–235PubMedCrossRef
26.
go back to reference Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, López-Otín C (2009) Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 94:840–849PubMedPubMedCentralCrossRef Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, López-Otín C (2009) Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 94:840–849PubMedPubMedCentralCrossRef
27.
go back to reference Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, Zabaneh D, Hoggart C, Bayele H, McCarthy MI, Peltonen L, Freimer NB, Srai SK, Maxwell PH, Sternberg MJ, Ruokonen A, Abecasis G, Jarvelin MR, Scott J, Elliott P, Kooner JS (2009) Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 41:1170–1172PubMedPubMedCentralCrossRef Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, Zabaneh D, Hoggart C, Bayele H, McCarthy MI, Peltonen L, Freimer NB, Srai SK, Maxwell PH, Sternberg MJ, Ruokonen A, Abecasis G, Jarvelin MR, Scott J, Elliott P, Kooner JS (2009) Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 41:1170–1172PubMedPubMedCentralCrossRef
29.
go back to reference Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transpl 28:1346–1359CrossRef Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transpl 28:1346–1359CrossRef
30.
go back to reference Drüeke TB, Parfrey PS (2012) Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 82:952–960PubMedCrossRef Drüeke TB, Parfrey PS (2012) Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 82:952–960PubMedCrossRef
31.
go back to reference Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef
32.
go back to reference Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA (2010) Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363:1146–1155PubMedCrossRef Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA (2010) Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363:1146–1155PubMedCrossRef
33.
go back to reference Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMedCrossRef Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMedCrossRef
34.
go back to reference Lindenblatt N, Menger MD, Klar E, Vollmar B (2007) Darbepoetin-alpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 27:1191–1198PubMedCrossRef Lindenblatt N, Menger MD, Klar E, Vollmar B (2007) Darbepoetin-alpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 27:1191–1198PubMedCrossRef
35.
go back to reference Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380:447–458PubMedCrossRef Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380:447–458PubMedCrossRef
36.
go back to reference Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, Pérez-Fernández M, Ortiz A (2019) Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol 39:1938–1966PubMedCrossRef Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, Pérez-Fernández M, Ortiz A (2019) Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol 39:1938–1966PubMedCrossRef
39.
go back to reference Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397:2060–2069PubMedCrossRef Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397:2060–2069PubMedCrossRef
40.
go back to reference Müller N, Schulte DM, Türk K, Freitag-Wolf S, Hampe J, Zeuner R, Schröder JO, Gouni-Berthold I, Berthold HK, Krone W, Rose-John S, Schreiber S, Laudes M (2015) IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 56:1034–1042PubMedPubMedCentralCrossRef Müller N, Schulte DM, Türk K, Freitag-Wolf S, Hampe J, Zeuner R, Schröder JO, Gouni-Berthold I, Berthold HK, Krone W, Rose-John S, Schreiber S, Laudes M (2015) IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 56:1034–1042PubMedPubMedCentralCrossRef
41.
go back to reference Fernandez-Prado R, Perez-Gomez MV, Ortiz A (2020) Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J 13:753–757PubMedPubMedCentralCrossRef Fernandez-Prado R, Perez-Gomez MV, Ortiz A (2020) Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J 13:753–757PubMedPubMedCentralCrossRef
42.
go back to reference Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H (2023) Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol 82:279–285PubMedCrossRef Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H (2023) Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol 82:279–285PubMedCrossRef
43.
go back to reference Chertow GM, Chang AM, Felker GM, Heise M, Velkoska E, Fellström B, Charytan DM, Clementi R, Gibson CM, Goodman SG, Jardine M, Levin A, Lokhnygina Y, Mears J, Mehran R, Stenvinkel P, Wang A, Wheeler DC, Zoccali C, Ridker PM, Mahaffey KW, Tricoci P, Wolf M (2024) IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med. https://doi.org/10.1038/s41591-024-03043-1CrossRefPubMedPubMedCentral Chertow GM, Chang AM, Felker GM, Heise M, Velkoska E, Fellström B, Charytan DM, Clementi R, Gibson CM, Goodman SG, Jardine M, Levin A, Lokhnygina Y, Mears J, Mehran R, Stenvinkel P, Wang A, Wheeler DC, Zoccali C, Ridker PM, Mahaffey KW, Tricoci P, Wolf M (2024) IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med. https://​doi.​org/​10.​1038/​s41591-024-03043-1CrossRefPubMedPubMedCentral
44.
go back to reference Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y (2002) Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20:304–311PubMedCrossRef Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y (2002) Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20:304–311PubMedCrossRef
45.
go back to reference Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M (2010) Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 69:741–746PubMedCrossRef Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M (2010) Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 69:741–746PubMedCrossRef
46.
go back to reference Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA (2021) A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32:708–722PubMedCrossRef Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA (2021) A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32:708–722PubMedCrossRef
47.
go back to reference Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A (2022) Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep 7:720–731PubMedPubMedCentralCrossRef Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A (2022) Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep 7:720–731PubMedPubMedCentralCrossRef
48.
go back to reference Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131PubMedCrossRef Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131PubMedCrossRef
49.
go back to reference Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 162:597–605PubMedCrossRef Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 162:597–605PubMedCrossRef
50.
go back to reference Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T (2012) Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739–2748PubMedCrossRef Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T (2012) Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739–2748PubMedCrossRef
51.
go back to reference Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH (2018) Inhibition of Interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405–2414PubMedCrossRef Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH (2018) Inhibition of Interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405–2414PubMedCrossRef
52.
go back to reference Woo J, Lu D, Lewandowski A, Xu H, Serrano P, Healey M, Yates DP, Beste MT, Libby P, Ridker PM, Steensma DP (2023) Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv 7:7471–7484PubMedPubMedCentralCrossRef Woo J, Lu D, Lewandowski A, Xu H, Serrano P, Healey M, Yates DP, Beste MT, Libby P, Ridker PM, Steensma DP (2023) Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv 7:7471–7484PubMedPubMedCentralCrossRef
53.
go back to reference Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jorgensen T, Danesh J (2014) Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 35:578–589PubMedCrossRef Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jorgensen T, Danesh J (2014) Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 35:578–589PubMedCrossRef
54.
go back to reference Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRef Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRef
55.
go back to reference Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG (2022) Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J 43:4832–4844PubMedCrossRef Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG (2022) Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J 43:4832–4844PubMedCrossRef
Metadata
Title
Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?
Authors
Mehmet Kanbay
Sidar Copur
Zeynep Y. Yilmaz
Francesca Mallamaci
Carmine Zoccali
Publication date
25-10-2024
Publisher
Springer International Publishing
Published in
Journal of Nephrology
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-024-02117-0

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more